ArticleCell death & disease2026
Evaluation of non-canonical p53 functions in DNA replication and recombination for variant classification.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Pathogenic germline TP53 variants predispose to diverse Li-Fraumeni syndrome (LFS) phenotypes and a broad cancer spectrum, whereby carriers of hypomorphic variants cluster in a cohort with attenuated disease onset and an overrepresentation of breast cancer (BC). Recently, functional assays have gained importance among the criteria used to predict the pathogenicity of hereditary breast and ovarian cancer (HBOC) risk-gene variants. Experimental assays scoring p53 functions in transcription and growth control have contributed to variant classification, yet a significant fraction of TP53 variants remain of unknown significance (VUS). To understand whether non-canonical functions of p53 in the fidelity control of DNA replication may aid variant classification, we subjected 23 TP53 VUS and 20 control variants identified in the German Consortium for HBOC (GC-HBOC) to assays that monitor nascent DNA synthesis and recombination-mediated bypass of replication barriers. Our results reveal a clear functional separation between benign (B)/likely benign (LB) and pathogenic (P)/likely pathogenic (LP) variants in recombination measurements, with B/LB variants associated with high recombination frequencies and P/LP variants with low recombination frequencies. Importantly, 8/23 VUS exhibited activities within the B/LB or P/LP ranges and therefore emerge as candidates for revised classification. Variant-specific recombination activities showed significant correlations with functional scores from four earlier studies systematically analyzing canonical p53 functions. Differently, in DNA fiber spreading assays B/LB and P/LP variants showed a more heterogeneous pattern and thus did not consistently recapitulate replication slow-down and acceleration observed in the presence and absence of p53, respectively. Structural modeling of separation-of-function (SOF) variants in transcription and recombination indicates varying effects on protein stability and the conformation of surface-exposed regions, affecting for example, the flexibility of Loop 1 (L1). Intriguingly, individual SOF variants suggest that loss-of-function (LOF) in recombination may drive BC, underscoring the predictive power of this assay for low-penetrance TP53 variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.